SOTIO Demonstrates Strong Potential of SOT102 (ADC Targeting Claudin 18.2) for Treatment of Solid Tumors in Preclinical Studies
April 12, 2021 09:00 ET
|
Sotio
Results from preclinical, proof-of-concept studies were presented at the 2021 AACR Annual MeetingResults demonstrate strong potential of SOT102 to eliminate tumor cells in a target-specific...
SOTIO to Present Preclinical Results Describing SOT102 as Treatment of Solid Tumors at the American Association of Cancer Research Annual Meeting
April 06, 2021 09:00 ET
|
Sotio
PRAGUE, Czech Republic, April 06, 2021 (GLOBE NEWSWIRE) -- SOTIO, a clinical stage immuno-oncology company owned by PPF Group, today announced the presentation of a virtual poster at the 2021...
SOTIO Presents Interim Data from its Phase 1/1b Study of SO-C101 in Patients with Advanced Solid Tumors at SITC 2020
November 11, 2020 09:00 ET
|
Sotio
Late breaking poster demonstrates SO-C101 was well tolerated to date with no dose-limiting toxicitiesConfirmed partial response was observed after SO-C101 monotherapy in a patient with skin squamous...
SOTIO to Present New Data on the IL-15 superagonist SO-C101 at the Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting
November 04, 2020 09:00 ET
|
Sotio
SOTIO will present three posters, including a late breaking poster on the clinical data from the ongoing Phase 1 study of IL-15 superagonist SO-C101 for the treatment of advanced solid tumors PRAGUE,...
SOTIO to Present at BIO-Europe Digital 2020
October 26, 2020 08:00 ET
|
Sotio
PRAGUE, Czech Republic, Oct. 26, 2020 (GLOBE NEWSWIRE) -- SOTIO, a clinical stage immuno-oncology company owned by PPF Group, today announced that Jens Hennecke, chief business officer of SOTIO, is...
SOTIO Acquires Rights to BOXR CAR-T Platform and Products from Unum Therapeutics
August 31, 2020 07:30 ET
|
Sotio
SOTIO will establish a T cell therapy R&D Center of Excellence in Cambridge, MassachusettsUnum’s former chief technology officer Geoff Hodge to join SOTIO to lead BOXR development team and all...
SOTIO to Present at the LifeSci Partners Summer Symposium
July 30, 2020 08:00 ET
|
Sotio
PRAGUE, Czech Republic, July 30, 2020 (GLOBE NEWSWIRE) -- SOTIO, a clinical stage immuno-oncology company owned by PPF Group, today announced that Radek Špíšek, chief executive officer of SOTIO,...
SOTIO Announces First Patient Dosed in Part B of Phase 1/1b Study with SO-C101 in Combination with Pembrolizumab in Patients with Solid Tumors
July 14, 2020 09:00 ET
|
Sotio
PRAGUE, Czech Republic, July 14, 2020 (GLOBE NEWSWIRE) -- SOTIO, a clinical stage immuno-oncology company owned by PPF Group, today announced that the first patient has been dosed in Part B of the...
SOTIO Appoints Richard Sachse as Chief Medical Officer
July 01, 2020 08:00 ET
|
Sotio
PRAGUE, Czech Republic, July 01, 2020 (GLOBE NEWSWIRE) -- SOTIO, a clinical stage immuno-oncology company owned by PPF Group, today announced the appointment of Richard Sachse, M.D., Ph.D., as chief...
SOTIO Presents New Data Showing Strong Anti-tumor Effect of IL-15 Superagonist SO-C101 in Mice at 2020 AACR Virtual Annual Meeting II
June 22, 2020 09:00 ET
|
Sotio
PRAGUE, June 22, 2020 (GLOBE NEWSWIRE) -- SOTIO and Cytune Pharma from the PPF Group, today presented new preclinical data highlighting the therapeutic potential of SO-C101, an IL-15 superagonist, as...